JP2015526443A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015526443A5 JP2015526443A5 JP2015527569A JP2015527569A JP2015526443A5 JP 2015526443 A5 JP2015526443 A5 JP 2015526443A5 JP 2015527569 A JP2015527569 A JP 2015527569A JP 2015527569 A JP2015527569 A JP 2015527569A JP 2015526443 A5 JP2015526443 A5 JP 2015526443A5
- Authority
- JP
- Japan
- Prior art keywords
- chloro
- indazol
- benzoyl
- trifluoromethyl
- cyclohex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 30
- -1 nitro, hydroxy Chemical group 0.000 claims 17
- 229910052736 halogen Inorganic materials 0.000 claims 14
- 150000002367 halogens Chemical class 0.000 claims 14
- 125000003545 alkoxy group Chemical group 0.000 claims 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 239000012453 solvate Substances 0.000 claims 12
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 8
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 8
- 239000002253 acid Substances 0.000 claims 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 4
- 125000004694 alkoxyaminocarbonyl group Chemical group 0.000 claims 4
- 125000005167 cycloalkylaminocarbonyl group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 2
- 102000001691 Member 3 Group F Nuclear Receptor Subfamily 1 Human genes 0.000 claims 2
- 108010029279 Member 3 Group F Nuclear Receptor Subfamily 1 Proteins 0.000 claims 2
- 125000004452 carbocyclyl group Chemical group 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- VOVNWNVFKASLLY-UHFFFAOYSA-N 4-[1-(2-chloro-6-cyclopropylbenzoyl)-4-fluoroindazol-3-yl]-1-methylcyclohex-3-ene-1-carboxylic acid Chemical compound C1C(C)(C(O)=O)CCC(C=2C3=C(F)C=CC=C3N(C(=O)C=3C(=CC=CC=3Cl)C3CC3)N=2)=C1 VOVNWNVFKASLLY-UHFFFAOYSA-N 0.000 claims 1
- FTKZZUUQKBDHIQ-UHFFFAOYSA-N 4-[1-(2-chloro-6-methylbenzoyl)-4-fluoroindazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound CC1=CC=CC(Cl)=C1C(=O)N1C2=CC=CC(F)=C2C(C=2CCC(CC=2)C(O)=O)=N1 FTKZZUUQKBDHIQ-UHFFFAOYSA-N 0.000 claims 1
- WGVKQEUIMVZKMX-UHFFFAOYSA-N 4-[1-(2-chloro-6-methylbenzoyl)pyrazolo[4,3-b]pyridin-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound CC1=CC=CC(Cl)=C1C(=O)N1C2=CC=CN=C2C(C=2CCC(CC=2)C(O)=O)=N1 WGVKQEUIMVZKMX-UHFFFAOYSA-N 0.000 claims 1
- DTFLTTVMFQVAJF-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-4-fluoroindazol-3-yl]-2-hydroxy-6-methylcyclohex-3-ene-1-carboxylic acid Chemical compound OC1C(C(O)=O)C(C)CC(C=2C3=C(F)C=CC=C3N(C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)N=2)=C1 DTFLTTVMFQVAJF-UHFFFAOYSA-N 0.000 claims 1
- ULSWXLRBFXSKOO-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-4-fluoroindazol-3-yl]-2-hydroxycyclohex-3-ene-1-carboxylic acid Chemical compound C1CC(C(O)=O)C(O)C=C1C(C1=C(F)C=CC=C11)=NN1C(=O)C1=C(Cl)C=CC=C1C(F)(F)F ULSWXLRBFXSKOO-UHFFFAOYSA-N 0.000 claims 1
- CHMFHAIDDKZQQX-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-4-fluoroindazol-3-yl]-4-methylcyclohexane-1-carboxylic acid Chemical compound N=1N(C(=O)C=2C(=CC=CC=2Cl)C(F)(F)F)C2=CC=CC(F)=C2C=1C1(C)CCC(C(O)=O)CC1 CHMFHAIDDKZQQX-UHFFFAOYSA-N 0.000 claims 1
- MZUYAAVZONNWFQ-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-4-fluoroindazol-3-yl]-5-methylcyclohex-3-ene-1-carboxylic acid Chemical compound CC1CC(C(O)=O)CC=C1C(C1=C(F)C=CC=C11)=NN1C(=O)C1=C(Cl)C=CC=C1C(F)(F)F MZUYAAVZONNWFQ-UHFFFAOYSA-N 0.000 claims 1
- DCEKJNKDTNIZBI-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-4-fluoroindazol-3-yl]-6-hydroxycyclohex-3-ene-1-carboxylic acid Chemical compound C1C(C(O)=O)C(O)CC(C=2C3=C(F)C=CC=C3N(C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)N=2)=C1 DCEKJNKDTNIZBI-UHFFFAOYSA-N 0.000 claims 1
- JAWOLYIAGCXUQG-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-4-fluoroindazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C1C(C(=O)O)CCC(C=2C3=C(F)C=CC=C3N(C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)N=2)=C1 JAWOLYIAGCXUQG-UHFFFAOYSA-N 0.000 claims 1
- RUZJPHPLVWPMFT-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-4-fluoroindazol-3-yl]cyclohex-3-ene-1-carboxylic acid;2-fluorobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1F.C1C(C(=O)O)CCC(C=2C3=C(F)C=CC=C3N(C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)N=2)=C1 RUZJPHPLVWPMFT-UHFFFAOYSA-N 0.000 claims 1
- PMCCAYCNHYFKOT-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-4-fluoroindol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C1C(C(=O)O)CCC(C=2C3=C(F)C=CC=C3N(C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)C=2)=C1 PMCCAYCNHYFKOT-UHFFFAOYSA-N 0.000 claims 1
- FHYRSAPXHJHYJO-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-(2-hydroxyethylcarbamoyl)indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C12=CC(C(=O)NCCO)=CC=C2C(C=2CCC(CC=2)C(O)=O)=NN1C(=O)C1=C(Cl)C=CC=C1C(F)(F)F FHYRSAPXHJHYJO-UHFFFAOYSA-N 0.000 claims 1
- DDQRUXMBXOJJAC-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-(2-methylmorpholine-4-carbonyl)indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C1COC(C)CN1C(=O)C1=CC=C(C(=NN2C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)C=3CCC(CC=3)C(O)=O)C2=C1 DDQRUXMBXOJJAC-UHFFFAOYSA-N 0.000 claims 1
- VHAZQHNDEZQPAZ-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-(3,3-difluoroazetidine-1-carbonyl)indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C1C(C(=O)O)CCC(C=2C3=CC=C(C=C3N(C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)N=2)C(=O)N2CC(F)(F)C2)=C1 VHAZQHNDEZQPAZ-UHFFFAOYSA-N 0.000 claims 1
- WYFJBTRWRCAZFU-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-(3-fluoroazetidine-1-carbonyl)indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C1C(C(=O)O)CCC(C=2C3=CC=C(C=C3N(C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)N=2)C(=O)N2CC(F)C2)=C1 WYFJBTRWRCAZFU-UHFFFAOYSA-N 0.000 claims 1
- QYKKDMJGDPIYER-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-(3-hydroxyazetidine-1-carbonyl)indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C1C(O)CN1C(=O)C1=CC=C(C(=NN2C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)C=3CCC(CC=3)C(O)=O)C2=C1 QYKKDMJGDPIYER-UHFFFAOYSA-N 0.000 claims 1
- GMWBIQXNRGCABM-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-(3-methoxyazetidine-1-carbonyl)indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C1C(OC)CN1C(=O)C1=CC=C(C(=NN2C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)C=3CCC(CC=3)C(O)=O)C2=C1 GMWBIQXNRGCABM-UHFFFAOYSA-N 0.000 claims 1
- YBBWSYMSKCZLKW-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-(3-methoxypyrrolidine-1-carbonyl)indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C1C(OC)CCN1C(=O)C1=CC=C(C(=NN2C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)C=3CCC(CC=3)C(O)=O)C2=C1 YBBWSYMSKCZLKW-UHFFFAOYSA-N 0.000 claims 1
- LQXRTKDPFNHPJT-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-(4-methyl-3-oxopiperazine-1-carbonyl)indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C1C(=O)N(C)CCN1C(=O)C1=CC=C(C(=NN2C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)C=3CCC(CC=3)C(O)=O)C2=C1 LQXRTKDPFNHPJT-UHFFFAOYSA-N 0.000 claims 1
- GXTKLCIXWCBOHM-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-(cyclopropylcarbamoyl)indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C1C(C(=O)O)CCC(C=2C3=CC=C(C=C3N(C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)N=2)C(=O)NC2CC2)=C1 GXTKLCIXWCBOHM-UHFFFAOYSA-N 0.000 claims 1
- YGFLUSDKSFGRBP-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-(dimethylcarbamoyl)indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C12=CC(C(=O)N(C)C)=CC=C2C(C=2CCC(CC=2)C(O)=O)=NN1C(=O)C1=C(Cl)C=CC=C1C(F)(F)F YGFLUSDKSFGRBP-UHFFFAOYSA-N 0.000 claims 1
- DSBPXNGBDIGBRF-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-(morpholine-4-carbonyl)indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C1C(C(=O)O)CCC(C=2C3=CC=C(C=C3N(C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)N=2)C(=O)N2CCOCC2)=C1 DSBPXNGBDIGBRF-UHFFFAOYSA-N 0.000 claims 1
- BOJKDICTPGZHJX-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-(piperidine-1-carbonyl)indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C1C(C(=O)O)CCC(C=2C3=CC=C(C=C3N(C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)N=2)C(=O)N2CCCCC2)=C1 BOJKDICTPGZHJX-UHFFFAOYSA-N 0.000 claims 1
- GRJJMWMGYUSJAR-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-(propan-2-ylcarbamoyl)indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C12=CC(C(=O)NC(C)C)=CC=C2C(C=2CCC(CC=2)C(O)=O)=NN1C(=O)C1=C(Cl)C=CC=C1C(F)(F)F GRJJMWMGYUSJAR-UHFFFAOYSA-N 0.000 claims 1
- VWMRDPIRRQMSDG-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-(pyrrolidine-1-carbonyl)indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C1C(C(=O)O)CCC(C=2C3=CC=C(C=C3N(C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)N=2)C(=O)N2CCCC2)=C1 VWMRDPIRRQMSDG-UHFFFAOYSA-N 0.000 claims 1
- WJSVXRQXYZLGEV-LDCVWXEPSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-[(2r)-2-methylpyrrolidine-1-carbonyl]indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C[C@@H]1CCCN1C(=O)C1=CC=C(C(=NN2C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)C=3CCC(CC=3)C(O)=O)C2=C1 WJSVXRQXYZLGEV-LDCVWXEPSA-N 0.000 claims 1
- DDQRUXMBXOJJAC-MYJWUSKBSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-[(2s)-2-methylmorpholine-4-carbonyl]indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C1CO[C@@H](C)CN1C(=O)C1=CC=C(C(=NN2C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)C=3CCC(CC=3)C(O)=O)C2=C1 DDQRUXMBXOJJAC-MYJWUSKBSA-N 0.000 claims 1
- WJSVXRQXYZLGEV-MYJWUSKBSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-[(2s)-2-methylpyrrolidine-1-carbonyl]indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C[C@H]1CCCN1C(=O)C1=CC=C(C(=NN2C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)C=3CCC(CC=3)C(O)=O)C2=C1 WJSVXRQXYZLGEV-MYJWUSKBSA-N 0.000 claims 1
- YBBWSYMSKCZLKW-UHUGOGIASA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-[(3r)-3-methoxypyrrolidine-1-carbonyl]indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C1[C@H](OC)CCN1C(=O)C1=CC=C(C(=NN2C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)C=3CCC(CC=3)C(O)=O)C2=C1 YBBWSYMSKCZLKW-UHUGOGIASA-N 0.000 claims 1
- WIWSXCVVUZWXLY-LDCVWXEPSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-[(3r)-3-methylmorpholine-4-carbonyl]indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C[C@@H]1COCCN1C(=O)C1=CC=C(C(=NN2C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)C=3CCC(CC=3)C(O)=O)C2=C1 WIWSXCVVUZWXLY-LDCVWXEPSA-N 0.000 claims 1
- YBBWSYMSKCZLKW-DAFXYXGESA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-[(3s)-3-methoxypyrrolidine-1-carbonyl]indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C1[C@@H](OC)CCN1C(=O)C1=CC=C(C(=NN2C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)C=3CCC(CC=3)C(O)=O)C2=C1 YBBWSYMSKCZLKW-DAFXYXGESA-N 0.000 claims 1
- WIWSXCVVUZWXLY-MYJWUSKBSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-[(3s)-3-methylmorpholine-4-carbonyl]indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C[C@H]1COCCN1C(=O)C1=CC=C(C(=NN2C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)C=3CCC(CC=3)C(O)=O)C2=C1 WIWSXCVVUZWXLY-MYJWUSKBSA-N 0.000 claims 1
- DBVPUALOJKWZOW-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-[1-hydroxy-3-(methylamino)propan-2-yl]oxycarbonylindazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C12=CC(C(=O)OC(CO)CNC)=CC=C2C(C=2CCC(CC=2)C(O)=O)=NN1C(=O)C1=C(Cl)C=CC=C1C(F)(F)F DBVPUALOJKWZOW-UHFFFAOYSA-N 0.000 claims 1
- RURBILVXTPQNGT-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-[2-hydroxyethyl(methyl)carbamoyl]indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C12=CC(C(=O)N(CCO)C)=CC=C2C(C=2CCC(CC=2)C(O)=O)=NN1C(=O)C1=C(Cl)C=CC=C1C(F)(F)F RURBILVXTPQNGT-UHFFFAOYSA-N 0.000 claims 1
- PPTPDSALMTVJCV-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-[2-methoxyethyl(methyl)carbamoyl]indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C12=CC(C(=O)N(C)CCOC)=CC=C2C(C=2CCC(CC=2)C(O)=O)=NN1C(=O)C1=C(Cl)C=CC=C1C(F)(F)F PPTPDSALMTVJCV-UHFFFAOYSA-N 0.000 claims 1
- ASIUHIHZWLCGSX-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-[cyclopropyl(methyl)carbamoyl]indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C=1C=C2C(C=3CCC(CC=3)C(O)=O)=NN(C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)C2=CC=1C(=O)N(C)C1CC1 ASIUHIHZWLCGSX-UHFFFAOYSA-N 0.000 claims 1
- MIVJIOPYWAUDFE-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-[methyl(propan-2-yl)carbamoyl]indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C12=CC(C(=O)N(C)C(C)C)=CC=C2C(C=2CCC(CC=2)C(O)=O)=NN1C(=O)C1=C(Cl)C=CC=C1C(F)(F)F MIVJIOPYWAUDFE-UHFFFAOYSA-N 0.000 claims 1
- WAZYMFVBHLCPOF-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C1C(C(=O)O)CCC(C=2C3=CC=CC=C3N(C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)N=2)=C1 WAZYMFVBHLCPOF-UHFFFAOYSA-N 0.000 claims 1
- SRNRFQGJGFHEGN-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]pyrazolo[4,3-b]pyridin-3-yl]-1-methylcyclohex-3-ene-1-carboxylic acid Chemical compound C1C(C)(C(O)=O)CCC(C=2C3=NC=CC=C3N(C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)N=2)=C1 SRNRFQGJGFHEGN-UHFFFAOYSA-N 0.000 claims 1
- RPNORSIVSACOLA-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]pyrazolo[4,3-b]pyridin-3-yl]-2-methylcyclohex-3-ene-1-carboxylic acid Chemical compound C1CC(C(O)=O)C(C)C=C1C(C1=NC=CC=C11)=NN1C(=O)C1=C(Cl)C=CC=C1C(F)(F)F RPNORSIVSACOLA-UHFFFAOYSA-N 0.000 claims 1
- PSTVSHJRDIVFDL-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]pyrazolo[4,3-b]pyridin-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C1C(C(=O)O)CCC(C=2C3=NC=CC=C3N(C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)N=2)=C1 PSTVSHJRDIVFDL-UHFFFAOYSA-N 0.000 claims 1
- OYBATLGLEZTBDT-UHFFFAOYSA-N 4-[4-chloro-1-[2-chloro-6-(trifluoromethyl)benzoyl]indazol-3-yl]-1-methylcyclohex-3-ene-1-carboxylic acid Chemical compound C1C(C)(C(O)=O)CCC(C=2C3=C(Cl)C=CC=C3N(C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)N=2)=C1 OYBATLGLEZTBDT-UHFFFAOYSA-N 0.000 claims 1
- MZQZGAYLGDXZIQ-UHFFFAOYSA-N 4-[6-(azetidine-1-carbonyl)-1-[2-chloro-6-(trifluoromethyl)benzoyl]indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C1C(C(=O)O)CCC(C=2C3=CC=C(C=C3N(C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)N=2)C(=O)N2CCC2)=C1 MZQZGAYLGDXZIQ-UHFFFAOYSA-N 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000011200 Kawasaki disease Diseases 0.000 claims 1
- IJFFCHQCDHHGDN-HAQNSBGRSA-N OC(=O)[C@H]1CC[C@@H](CC1)c1nn(C(=O)c2c(Cl)cccc2C(F)(F)F)c2cccc(F)c12 Chemical compound OC(=O)[C@H]1CC[C@@H](CC1)c1nn(C(=O)c2c(Cl)cccc2C(F)(F)F)c2cccc(F)c12 IJFFCHQCDHHGDN-HAQNSBGRSA-N 0.000 claims 1
- GNTUJCVVEKHONG-HAQNSBGRSA-N OC(=O)[C@H]1CC[C@@H](CC1)c1nn(C(=O)c2c(Cl)cccc2C(F)(F)F)c2cccnc12 Chemical compound OC(=O)[C@H]1CC[C@@H](CC1)c1nn(C(=O)c2c(Cl)cccc2C(F)(F)F)c2cccnc12 GNTUJCVVEKHONG-HAQNSBGRSA-N 0.000 claims 1
- GNTUJCVVEKHONG-TXEJJXNPSA-N OC(=O)[C@H]1CC[C@H](CC1)c1nn(C(=O)c2c(Cl)cccc2C(F)(F)F)c2cccnc12 Chemical compound OC(=O)[C@H]1CC[C@H](CC1)c1nn(C(=O)c2c(Cl)cccc2C(F)(F)F)c2cccnc12 GNTUJCVVEKHONG-TXEJJXNPSA-N 0.000 claims 1
- 102000016978 Orphan receptors Human genes 0.000 claims 1
- 108070000031 Orphan receptors Proteins 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- VZFUCHSFHOYXIS-UHFFFAOYSA-N cycloheptane carboxylic acid Natural products OC(=O)C1CCCCCC1 VZFUCHSFHOYXIS-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000000626 mucocutaneous leishmaniasis Diseases 0.000 claims 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 102000003702 retinoic acid receptors Human genes 0.000 claims 1
- 108090000064 retinoic acid receptors Proteins 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- QSERINUGEFDOOJ-UHFFFAOYSA-N CC(N1N(C)C1)S=O Chemical compound CC(N1N(C)C1)S=O QSERINUGEFDOOJ-UHFFFAOYSA-N 0.000 description 1
- 0 CCSc1cccc(*)c1C(N(*=C(C1=*S)C2=CCC(*)CC2)C1=**=*)=O Chemical compound CCSc1cccc(*)c1C(N(*=C(C1=*S)C2=CCC(*)CC2)C1=**=*)=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2012/080133 WO2014026328A1 (en) | 2012-08-15 | 2012-08-15 | 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof |
| CNPCT/CN2012/080133 | 2012-08-15 | ||
| PCT/US2013/054902 WO2014028597A2 (en) | 2012-08-15 | 2013-08-14 | 3-CYCLOHEXENYL AND CYCLOHEXYL SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015526443A JP2015526443A (ja) | 2015-09-10 |
| JP2015526443A5 true JP2015526443A5 (enExample) | 2016-09-23 |
| JP6232429B2 JP6232429B2 (ja) | 2017-11-15 |
Family
ID=50101186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015527569A Expired - Fee Related JP6232429B2 (ja) | 2012-08-15 | 2013-08-14 | ＲＯＲγＴ阻害剤としての３−シクロヘキセニルおよびシクロヘキシル置換インドールおよびインダゾール化合物およびそれらの使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9487490B2 (enExample) |
| EP (1) | EP2884976B1 (enExample) |
| JP (1) | JP6232429B2 (enExample) |
| KR (1) | KR20150041800A (enExample) |
| CN (1) | CN104822376A (enExample) |
| AU (1) | AU2013302644A1 (enExample) |
| BR (1) | BR112015003332A2 (enExample) |
| CA (1) | CA2881696A1 (enExample) |
| CY (1) | CY1122272T1 (enExample) |
| DK (1) | DK2884976T3 (enExample) |
| ES (1) | ES2749713T3 (enExample) |
| HR (1) | HRP20191654T1 (enExample) |
| HU (1) | HUE045379T2 (enExample) |
| LT (1) | LT2884976T (enExample) |
| ME (1) | ME03579B (enExample) |
| PL (1) | PL2884976T3 (enExample) |
| PT (1) | PT2884976T (enExample) |
| RS (1) | RS59364B1 (enExample) |
| RU (1) | RU2015108898A (enExample) |
| SI (1) | SI2884976T1 (enExample) |
| SM (1) | SMT201900580T1 (enExample) |
| WO (2) | WO2014026328A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2487159A1 (en) | 2011-02-11 | 2012-08-15 | MSD Oss B.V. | RorgammaT inhibitors |
| WO2014026327A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof |
| WO2014026330A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
| WO2014026329A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof |
| ES2685839T3 (es) * | 2013-08-02 | 2018-10-11 | Pfizer Inc. | Inhibidores de RORC2 heterobicicloarilo y procedimientos de uso de los mismos |
| KR102408261B1 (ko) | 2014-02-03 | 2022-06-10 | 비타이 파마슈티컬즈, 엘엘씨 | Ror-감마의 디하이드로피롤로피리딘 저해제 |
| JP2017507950A (ja) | 2014-02-27 | 2017-03-23 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法 |
| US9896441B2 (en) | 2014-05-05 | 2018-02-20 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
| JP6523337B2 (ja) | 2014-05-05 | 2019-05-29 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | ＲＯＲγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物 |
| EP3172195A4 (en) | 2014-07-25 | 2018-03-21 | Innov17 LLC | Sulfonamide retinoic acid receptor-related orphan receptor modulators and uses thereof |
| WO2016014918A1 (en) * | 2014-07-25 | 2016-01-28 | Innov 17 Llc | Benzimidazole retinoic acid receptor-related orphan receptor modulators and uses thereof |
| US9884847B2 (en) | 2014-07-25 | 2018-02-06 | Innov17 Llc | Indazole retinoic acid receptor-related orphan receptor modulators and uses thereof |
| US20160024086A1 (en) * | 2014-07-25 | 2016-01-28 | Innov17 Llc | Azaindole retinoic acid receptor-related orphan receptor modulators and uses thereof |
| MA40759A (fr) | 2014-09-26 | 2017-08-01 | Pfizer | Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation |
| DK3207043T6 (da) | 2014-10-14 | 2020-01-20 | Vitae Pharmaceuticals Llc | Dihydropyrrolopyridin-inhibitorer af ror-gamma |
| GB201419015D0 (en) | 2014-10-24 | 2014-12-10 | Orca Pharmaceuticals Ltd | Compounds |
| US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| EP3242878B1 (en) * | 2015-01-08 | 2020-10-14 | Impetis Biosciences Ltd. | Bicyclic compounds, compositions and medicinal applications thereof |
| US10322108B2 (en) | 2015-01-28 | 2019-06-18 | Beijing Hanmi Pharmaceutical Co., Ltd. | N-benzoate group substituted benzopyrroline-2-one derivative and use thereof |
| EP3250561A1 (en) | 2015-01-30 | 2017-12-06 | Pfizer Inc | Sulfonamide-subsituted indole modulators of rorc2 and methods of use thereof |
| WO2016130818A1 (en) | 2015-02-11 | 2016-08-18 | Merck Sharp & Dohme Corp. | SUBSTITUTED PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
| WO2016128908A1 (en) * | 2015-02-12 | 2016-08-18 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
| CN107614062A (zh) | 2015-03-12 | 2018-01-19 | 加利福尼亚大学董事会 | 用RORγ抑制剂治疗癌症的方法 |
| AU2016257997A1 (en) | 2015-05-05 | 2017-11-09 | Lycera Corporation | Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease |
| PT3307734T (pt) | 2015-06-09 | 2020-02-25 | Abbvie Inc | Moduladores de recetores nucleares (ror) para o tratamento de doenças inflamatórias e autoimunes |
| WO2016198908A1 (en) * | 2015-06-09 | 2016-12-15 | Abbvie Inc. | Ror nuclear receptor modulators |
| AU2016276947A1 (en) | 2015-06-11 | 2017-12-14 | Lycera Corporation | Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease |
| US10301261B2 (en) | 2015-08-05 | 2019-05-28 | Vitae Pharmaceuticals, Llc | Substituted indoles as modulators of ROR-gamma |
| AR105821A1 (es) * | 2015-09-09 | 2017-11-15 | Lilly Co Eli | COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T |
| EP3368516B1 (en) * | 2015-10-27 | 2020-07-15 | Merck Sharp & Dohme Corp. | SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
| EP3368535B1 (en) | 2015-10-27 | 2020-12-02 | Merck Sharp & Dohme Corp. | Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof |
| MX2018005004A (es) * | 2015-10-27 | 2018-09-12 | Merck Sharp & Dohme | Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos. |
| EP3868750A1 (en) | 2015-11-20 | 2021-08-25 | Vitae Pharmaceuticals, LLC | Modulators of ror-gamma |
| TWI757266B (zh) | 2016-01-29 | 2022-03-11 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| AU2017388054B2 (en) | 2016-12-28 | 2022-03-24 | Dart Neuroscience, Llc | Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors |
| JP2020111510A (ja) * | 2017-03-29 | 2020-07-27 | 科研製薬株式会社 | インダゾール誘導体及びそれを含有する医薬 |
| ES2924359T3 (es) * | 2017-04-11 | 2022-10-06 | Sunshine Lake Pharma Co Ltd | Compuestos de indazol sustituidos con flúor y usos de los mismos |
| WO2019007382A1 (zh) * | 2017-07-06 | 2019-01-10 | 江苏恒瑞医药股份有限公司 | 吲哚甲酰胺类衍生物、其制备方法及其在医药上的应用 |
| CN111225914B (zh) | 2017-07-24 | 2022-10-11 | 生命医药有限责任公司 | RORγ的抑制剂 |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| CA3120971A1 (en) | 2017-11-27 | 2019-05-31 | Dart Neuroscience, Llc | Substituted furanopyrimidine compounds as pde1 inhibitors |
| CN120418228A (zh) * | 2023-01-09 | 2025-08-01 | 康百达（四川）生物医药科技有限公司 | 一种杂环化合物及其在医药上的应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT95899A (pt) * | 1989-11-17 | 1991-09-13 | Glaxo Group Ltd | Processo para a preparacao de derivados indole |
| WO1995027202A1 (en) * | 1994-03-30 | 1995-10-12 | Ciba-Geigy Ag | Screening method using the rzr receptor family |
| US5639780A (en) * | 1995-05-22 | 1997-06-17 | Merck Frosst Canada, Inc. | N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors |
| US6716452B1 (en) * | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| PE20060417A1 (es) | 2004-08-03 | 2006-06-13 | Wyeth Corp | Indazoles como moduladores de lxrs |
| US7405215B2 (en) * | 2004-09-21 | 2008-07-29 | Wyeth | Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof |
| EP1828180A4 (en) * | 2004-12-08 | 2010-09-15 | Glaxosmithkline Llc | 1H-pyrrolo [2,3-BETA] PYRIDINE |
| EP2181710A1 (en) * | 2008-10-28 | 2010-05-05 | Phenex Pharmaceuticals AG | Ligands for modulation of orphan receptor-gamma (NR1F3) activity |
| EP2459184A1 (en) * | 2009-07-31 | 2012-06-06 | The Brigham and Women's Hospital, Inc. | Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses |
| WO2011055270A1 (en) * | 2009-11-04 | 2011-05-12 | Wyeth Llc | Indole based receptor crth2 antagonists |
| EP2487159A1 (en) | 2011-02-11 | 2012-08-15 | MSD Oss B.V. | RorgammaT inhibitors |
| JP2014166961A (ja) * | 2011-06-20 | 2014-09-11 | Dainippon Sumitomo Pharma Co Ltd | 新規インダゾール誘導体 |
| WO2014026330A1 (en) * | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
| WO2014026329A1 (en) * | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof |
| WO2014026327A1 (en) * | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof |
-
2012
- 2012-08-15 WO PCT/CN2012/080133 patent/WO2014026328A1/en not_active Ceased
-
2013
- 2013-08-14 HR HRP20191654 patent/HRP20191654T1/hr unknown
- 2013-08-14 PL PL13829099T patent/PL2884976T3/pl unknown
- 2013-08-14 SI SI201331578T patent/SI2884976T1/sl unknown
- 2013-08-14 JP JP2015527569A patent/JP6232429B2/ja not_active Expired - Fee Related
- 2013-08-14 RU RU2015108898A patent/RU2015108898A/ru unknown
- 2013-08-14 LT LTEP13829099.4T patent/LT2884976T/lt unknown
- 2013-08-14 DK DK13829099.4T patent/DK2884976T3/da active
- 2013-08-14 BR BR112015003332A patent/BR112015003332A2/pt not_active IP Right Cessation
- 2013-08-14 CN CN201380053426.7A patent/CN104822376A/zh active Pending
- 2013-08-14 CA CA2881696A patent/CA2881696A1/en not_active Abandoned
- 2013-08-14 KR KR20157006342A patent/KR20150041800A/ko not_active Abandoned
- 2013-08-14 WO PCT/US2013/054902 patent/WO2014028597A2/en not_active Ceased
- 2013-08-14 AU AU2013302644A patent/AU2013302644A1/en not_active Abandoned
- 2013-08-14 PT PT138290994T patent/PT2884976T/pt unknown
- 2013-08-14 ME MEP-2019-276A patent/ME03579B/me unknown
- 2013-08-14 HU HUE13829099A patent/HUE045379T2/hu unknown
- 2013-08-14 ES ES13829099T patent/ES2749713T3/es active Active
- 2013-08-14 RS RSP20191289 patent/RS59364B1/sr unknown
- 2013-08-14 US US14/421,057 patent/US9487490B2/en active Active
- 2013-08-14 EP EP13829099.4A patent/EP2884976B1/en active Active
- 2013-08-14 SM SM20190580T patent/SMT201900580T1/it unknown
-
2019
- 2019-10-04 CY CY20191101047T patent/CY1122272T1/el unknown